儿童银屑病生物制剂药物生存率真实世界回顾性研究
该回顾性观察研究纳入134例儿童银屑病患者,分析184个疗程(依那西普70、阿达木单抗68、乌司奴单抗46),发现乌司奴单抗药物生存率显著优于阿达木单抗和依那西普,严重不良事件谱与成人相似。
要点
- 乌司奴单抗在儿童银屑病中药物生存率最高
- 阿达木单抗多用于基线病情更重、发病更早的患儿
- 严重不良事件包括感染、体重增加和银屑病 flare,多可管理
核心结论
- 乌司奴单抗在儿童银屑病真实世界中药物生存率最佳。
- 儿童严重不良事件谱与成人相似。
研究设计与样本
- 观察性回顾性研究,从134例儿童临床记录中提取数据。
- 共分析184个生物制剂疗程:依那西普70、阿达木单抗68、乌司奴单抗46。
- 采用Kaplan-Meier法分析总体及亚组药物生存率。
主要发现
- 乌司奴单抗药物生存率在所有治疗、所有银屑病类型、斑块型、生物制剂初治及经治患者中均高于阿达木单抗和依那西普(P<0.0001、P=0.0003、P=0.0007、P=0.007)。
- 选择一线生物制剂的因素包括:起始年龄(阿达木单抗更年轻,P<0.0001)、银屑病发病年龄(阿达木单抗和依那西普更年轻,P=0.03)、基线PASI和PGA(阿达木单抗更高,P<0.001)。
- 报告8例严重不良事件:严重感染3例、显著体重增加2例、银屑病 flare 1例、不适1例。
- 3例患儿因不良事件停药(1例银屑病 flare,2例体重增加),仅2例体重增加结局不佳。
关键数值与推荐
- 药物生存率比较:乌司奴单抗 vs 阿达木单抗和依那西普,总体P<0.0001,斑块型P=0.0003,初治P=0.0007,经治P=0.007。
- 严重不良事件共8例,包括感染3例、体重增加2例、银屑病 flare 1例、不适1例。
临床怎么用
- 在儿童银屑病日常实践中,乌司奴单抗可能具有更优的长期维持效果。
- 选择生物制剂时需考虑患儿年龄、发病年龄及基线疾病严重程度。
- 需监测严重感染和体重增加等不良事件。
局限性
- 回顾性观察设计,可能存在选择偏倚和信息偏倚。
- 样本量有限(134例患儿,184个疗程)。
- 数据来自单中心日常实践,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three biotherapies - etanercept, adalimumab and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long-term performance in real-life settings. OBJECTIVE: The objective of this study was to evaluate the survival rates of biological therapies in children with psoriasis in real-life conditions. Secondary objectives were to evaluate the factors associated with the choice of the biological therapy and to report severe adverse events. MATERIALS AND METHODS: This study was an observational retrospective study. Data were extracted from the clinical records of 134 children. Kaplan-Meier estimates were used to analyse drug survival overall and in subgroups of plaque psoriasis, bio-naïve and non-naïve patients. RESULTS: We analysed 184 treatment courses: 70 with etanercept, 68 with adalimumab and 46 with ustekinumab. Factors associated with the choice of first-line biological agent were age at initiation (younger for adalimumab, P < 0.0001), age at onset of psoriasis (younger for adalimumab and etanercept, P = 0.03) and baseline Psoriasis Assessment Severity Index and Physician global assessment (both higher for adalimumab, P < 0.001). Drug survival rates were higher for ustekinumab than for adalimumab and etanercept (P < 0.0001) for all treatment and all psoriasis types, plaque-type psoriasis (P = 0.0003), patients naïve for biological agents (P = 0.0007) and non-naïve patients (P = 0.007). We reported eight serious adverse events (SAEs): severe infections (n = 3), significant weight gain (n = 2), psoriasis flare (n = 1) and malaise (n = 1). Biological therapy was discontinued in three children (one with psoriasis flare and two with weight gain). Only the two cases of weight gain resulted in an unfavourable outcome. CONCLUSIONS: Our real-life comparative study found that ustekinumab had the best drug survival outcome. The profile of SAEs in children was comparable to that in adults. These results will assist dermatologists in the decision-making process when choosing treatment options for children with psoriasis in daily practice.
引用
- Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 30883928. doi:10.1111/jdv.15579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。